DIABETIC MACULAR OEDEMA
A randomised study involving 111 eyes of 105 patients with diabetic macular oedema showed that, compared with baseline values, visual acuity improved significantly more at three and six months among patients receiving triamcinolone alone or in combination with bevacizumab than in eyes receiving bevacizumab alone. All three treatments produce significant reductions in central macular thickness throughout follow-up, with greater reductions during the first months of therapy in the triamcinolone groups. However, by 12 months the groups had statistically similar results in terms of both macular thickness and visual acuity
(Lim et al, Ophthalmologica 2012; 227: 00-106).
Latest Articles
Beyond the Numbers
Empowering patient participation fosters continuous innovation in cataract surgery.
Thinking Beyond the Surgery Room
Practice management workshop focuses on financial operations and AI business applications.
Picture This: Photo Contest Winners
ESCRS 2025 Refractive and Cataract Photo Contest winners.
Aid Cuts Threaten Global Eye Care Progress
USAID closure leads retreat in development assistance.
Supplement: ESCRS Clinical Trends Series: Presbyopia
Nutrition and the Eye: A Recipe for Success
A look at the evidence for tasty ways of lowering risks and improving ocular health.
New Award to Encourage Research into Sustainable Practices
Sharing a Vision for the Future
ESCRS leaders update Trieste conference on ESCRS initiatives.
Extending Depth of Satisfaction
The ESCRS Eye Journal Club discuss a new study reviewing the causes and management of dissatisfaction after implantation of an EDOF IOL.
Conventional Versus Laser-Assisted Cataract Surgery
Evidence favours conventional technique in most cases.